Patient-reported Outcomes in Patients With Primary Advanced or Recurrent Endometrial Cancer Who Received Dostarlimab Plus Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel in the ENGOT-EN6/GOG3031/RUBY Trial.

MLA

Mirza, Mansoor Raza, et al. “Patient-Reported Outcomes in Patients With Primary Advanced or Recurrent Endometrial Cancer Who Received Dostarlimab Plus Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel in the ENGOT-EN6/GOG3031/RUBY Trial.” Journal of Oncology Navigation & Survivorship, vol. 14, no. 11, Nov. 2023, p. 361. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=173646447&authtype=sso&custid=ns315887.

APA

Mirza, M. R., Powell, M. A., Lundgren, C., Sukhin, V., & Pothuri, B. (2023). Patient-reported Outcomes in Patients With Primary Advanced or Recurrent Endometrial Cancer Who Received Dostarlimab Plus Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel in the ENGOT-EN6/GOG3031/RUBY Trial. Journal of Oncology Navigation & Survivorship, 14(11), 361.

Chicago

Mirza, Mansoor Raza, Matthew A. Powell, Caroline Lundgren, Vladyslav Sukhin, and Bhavana Pothuri. 2023. “Patient-Reported Outcomes in Patients With Primary Advanced or Recurrent Endometrial Cancer Who Received Dostarlimab Plus Carboplatin-Paclitaxel vs Carboplatin-Paclitaxel in the ENGOT-EN6/GOG3031/RUBY Trial.” Journal of Oncology Navigation & Survivorship 14 (11): 361. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=173646447&authtype=sso&custid=ns315887.